Last updated: 2026-09-15 21:41:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Moderna, Inc. (MRNA) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $143.78, with a market capitalization of $57.48B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $22.28 to $176.66. This page covers its latest market performance, valuation, price trends and company information.
$57.48B | |
$146.00 | |
$1,420.00 | |
$7.10 | |
$146.69 | |
6.75M | |
16.19M | |
-- | |
$176.66 | |
$22.28 | |
-- | |
-- |
Moderna, Inc. (MRNA) is trading at $143.84 in after-hours trading as of 2026-09-15 21:39:00, down 1.95% ($2.85) from the regular-session close of $146.69.
After-hours trading shows how investors are pricing MRNA after the regular session closes. The current after-hours price is below the regular-session close, indicating cautious after-hours sentiment.
Over the past seven days, Moderna, Inc. (MRNA) moved from $148.87 to $143.78, representing a decline of 3.42% ($5.09).
The stock traded between $130.38 and $154.69 during the period. The latest price is near the middle of the 7-day range, indicating moderate downward.
The average daily volume was 11.64 million shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 78.7%
MRNA is currently trading at $143.78, placing it 78.7% of the way from its 52-week low of $22.28 to its 52-week high of $176.66. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 25 mRNA development candidates in clinical studies as of March 2026. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 4700 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Moderna, Inc. (MRNA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.